Home >> Multiple System Atrophy >> Medical Journal Articles on MSA
Medical Journal Articles on MSA
Decreased retinal sensitivity and loss of retinal nerve fibers in multiple system atrophy.
Fischer MD, et al. Graefes Arch Clin Exp Ophthalmol. 2012 Aug. [Epub ahead of print]
Analysis of colonic alpha-synuclein pathology in multiple system atrophy.
Pouclet H, et al. Parkinsonism Relat Disord. 2012 Aug; 18(7):893-5.
Is peripheral neuron degeneration involved in multiple system atrophy? A clinical and electrophysiological study.
Gawel M, et al. J Neurol Sci. 2012 Aug; 319(1-2):81-5.
Is there delayed gastric emptying in patients with multiple system atrophy? An analysis using the (13)C-acetate breath test.
Tanaka Y, et al. J Neurol. 2012 Jul; 259(7):1448-52.
Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy.
Ishigami N, et al. Mov Disord. 2012 Jun; 27(7):851-7.
Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes.
Schwarz L, et al. J Mol Neurosci. 2012 Jun; 47(2):256-66.
Network correlates of disease severity in multiple system atrophy.
Poston KL, et al. Neurology. 2012 Apr; 78(16):1237-44.
Sleep-disordered breathing in neurodegenerative diseases.
Gaig C, et al. Curr Neurol Neurosci Rep. 2012 Apr; 12(2):205-17.
Activation and alteration of lysosomes in multiple system atrophy.
Makioka K, et al. Neuroreport. 2012 Mar; 23(5):270-6.
White matter hyperintensities in patients with multiple system atrophy.
Umoto M, et al. Parkinsonism Relat Disord. 2012 Jan; 18(1):17-20.
Eye movement disturbance in multiple system atrophy: chronological study of 50 patients.
Isozaki E, et al. Rinsho Shinkeigaku. 2012; 52(4):218-26.
Blood-brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy.
Song SK, et al. Neurobiol Aging. 2011 Dec; 32(12):2183-9.
Multiple system atrophy - synuclein and neuronal degeneration.
Yoshida M. Rinsho Shinkeigaku. 2011 Nov; 51(11):838-42.
Genetic players in multiple system atrophy: unfolding the nature of the beast. (SLEEMSA study).
Stemberger S, et al. Neurobiol Aging. 2011 Oct; 32(10):1924.e5-14.
Protein disulfide isomerase immunopositive glial cytoplasmic inclusions in patients with multiple system atrophy.
Honjo Y, et al. Int J Neurosci. 2011 Oct; 121(10):543-50.
Altered regional homogeneity in motor cortices in patients with multiple system atrophy.
You H, et al. Neurosci Lett. 2011 Sep; 502(1):18-23.
Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons.
Stefanova N, et al. Am J Pathol. 2011 Aug; 179(2):954-63.
Uric acid as a potential disease modifier in patients with multiple system atrophy.
Lee JE, et al. Mov Disord. 2011 Jul; 26(8):1533-6.
Brainstem metabolites in multiple system atrophy of cerebellar type: 3.0-T magnetic resonance spectroscopy study.
Takado Y, et al. Mov Disord. 2011 Jun; 26(7):1297-302.
Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy.
Sasaki H, et al. Mol Brain. 2011 Jun; 4:24.
Nonmotor presentations of multiple system atrophy.
Colosimo C. Nat Rev Neurol. 2011 May; 7(5):295-8.
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy.
Wang Y, et al. Am J Pathol. 2011 Apr; 178(4):1509-16.
Treatment of dysautonomia in extrapyramidal disorders.
Ziemssen T, et al. Ther Adv Neurol Disord. 2010 Jan; 3(1):53-67.
Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation.
Hirohata M, et al. Neurosci Lett. 2011 Mar;491(1):48-52.
The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy.
De Cock VC, et al. Brain. 2011 Mar; 134(Pt 3):856-62.
Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study).
Moreno-Lopez C, et al. Arch Neurol. 2011 Feb; 68(2):223-30.
MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy.
Vilarino-Guell C, et al. Neurology. 2011 Feb; 76(7):670-2.
Association of metallothionein-III with oligodendroglial cytoplasmic inclusions in multiple system atrophy.
Pountney DL, et al. Neurotox Res. 2011 Jan; 19(1):115-22.
Differential involvement of the periaqueductal gray in multiple system atrophy.
Benarroch EE, et al. Auton Neurosci. 2010 Dec; 158(1-2):111-7.
Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system.
Pellecchia MT, et al. Mov Disord. 2010 Nov; 25(15):2621-6.
Involvement of endoplasmic reticulum stress defined by activated unfolded protein response in multiple system atrophy.
Makioka K, et al. J Neurol Sci. 2010 Oct; 297(1-2):60-5.
Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy.
Levy R, et al. Exp Brain Res. 2010 Sep; 206(1):1-13.
The close relationship between life-threatening breathing disorders and urine storage dysfunction in multiple system atrophy.
Deguchi K, et al. J Neurol. 2010 Aug; 257(8):1287-92.
Multiple system atrophy: current and future approaches to management.
Flabeau O, et al. Ther Adv Neurol Disord. 2010 Jul; 3(4):249-63.
Tremulous arytenoid movements predict severity of glottic stenosis in multiple system atrophy.
Ozawa T, et al. Mov Disord. 2010 Jul; 25(10):1418-23.
Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update.
Jellinger KA, et al. Acta Neuropathol. 2010 Jun; 119(6):657-67.
Involvement of 4-hydroxy-2-nonenal accumulation in multiple system atrophy.
Shibata N, et al. Acta Histochem Cytochem. 2010 May; 43(2):69-75.
Ventilatory and cardiovascular responses to hypercapnia and hypoxia in multiple-system atrophy.
Lipp A, et al. Arch Neurol. 2010 Feb; 67(2):211-6.
LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Huang Y, et al. Acta Neuropathol. 2008 Dec; 116(6):639-46.
Second consensus statement on the diagnosis of multiple system atrophy.
Gilman S, et al. Neurology. 2008 Aug; 71(9):670-6.
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.
Bartels AL, et al. J Neural Transm. 2008 Jul; 115(7):1001-9.
Loss of A5 noradrenergic neurons in multiple system atrophy.
Benarroch EE, et al. Acta Neuropathol. 2008 Jun; 115(6):629-34.
Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients.
Anderson T, et al. Mov Disord. 2008 May 15; 23(7):977-84.
Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy.
Lyoo CH, et al. Brain. 2008 Feb; 131(Pt 2):438-46.
Sleep and breathing in multiple system atrophy.
Iranzo A. Curr Treat Options Neurol. 2007 Sep; 9(5):347-53.
Calf venous compliance in multiple system atrophy.
Lipp A, et al. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H260-5.
Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy.
Sato K, et al. Mov Disord. 2007 Apr; 22(5):738-42.
Depletion of putative chemosensitive respiratory neurons in the ventral medullary surface in multiple system atrophy.
Benarroch EE, et al. Brain. 2007 Feb; 130(Pt 2):469-75.
| | |
|
|
|
